Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (404) 404
science & technology (392) 392
life sciences & biomedicine (385) 385
canagliflozin (342) 342
diabetes mellitus, type 2 - drug therapy (334) 334
hypoglycemic agents - therapeutic use (265) 265
diabetes (220) 220
canagliflozin - therapeutic use (217) 217
male (201) 201
type 2 diabetes (193) 193
female (181) 181
glucosides - therapeutic use (176) 176
sodium-glucose transporter 2 - antagonists & inhibitors (171) 171
glucose (167) 167
middle aged (163) 163
endocrinology & metabolism (157) 157
aged (131) 131
hypoglycemic agents - adverse effects (125) 125
treatment outcome (105) 105
pharmacology & pharmacy (104) 104
benzhydryl compounds - therapeutic use (102) 102
dapagliflozin (102) 102
thiophenes - therapeutic use (102) 102
diabetes mellitus (99) 99
canagliflozin - adverse effects (98) 98
diabetes mellitus, type 2 - blood (97) 97
adult (94) 94
type 2 diabetes mellitus (92) 92
empagliflozin (87) 87
dextrose (84) 84
blood glucose - drug effects (75) 75
general & internal medicine (75) 75
glucosides - adverse effects (75) 75
medicine, general & internal (75) 75
blood glucose - metabolism (73) 73
hypoglycemic agents - administration & dosage (73) 73
sodium (73) 73
blood pressure (70) 70
body weight (69) 69
drug therapy (69) 69
sglt2 inhibitor (68) 68
clinical trials (66) 66
hypoglycemic agents - pharmacology (66) 66
insulin (62) 62
double-blind method (61) 61
sodium-glucose transporter 2 inhibitors - therapeutic use (61) 61
risk factors (59) 59
care and treatment (58) 58
canagliflozin - pharmacology (57) 57
animals (56) 56
diabetes mellitus, type 2 - complications (56) 56
internal medicine (56) 56
canagliflozin - administration & dosage (55) 55
diabetes mellitus, type 2 - metabolism (54) 54
sodium-glucose transporter 2 - metabolism (54) 54
analysis (50) 50
diabetes therapy (50) 50
glucosides - pharmacology (50) 50
glycated hemoglobin a - metabolism (50) 50
drug therapy, combination (49) 49
thiophenes - adverse effects (48) 48
patients (47) 47
abridged index medicus (46) 46
hypoglycemic agents (45) 45
hemoglobin (44) 44
randomized controlled trials as topic (44) 44
blood pressure - drug effects (42) 42
medicine & public health (42) 42
cardiovascular disease (40) 40
research (39) 39
dose-response relationship, drug (38) 38
glucosides - administration & dosage (38) 38
sodium-glucose transporter 2 inhibitors - adverse effects (38) 38
endocrinology (37) 37
review (37) 37
diabetes mellitus, type 2 - physiopathology (36) 36
glucose transporter (36) 36
studies (36) 36
benzhydryl compounds - adverse effects (35) 35
glycosylated hemoglobin (35) 35
hyperglycemia (35) 35
medical research (35) 35
body weight - drug effects (34) 34
cardiovascular system & cardiology (34) 34
hypoglycemia (34) 34
safety (34) 34
benzhydryl compounds - pharmacology (33) 33
diabetes mellitus, type 2 - epidemiology (33) 33
medicine, research & experimental (33) 33
metformin (33) 33
metformin - therapeutic use (33) 33
research & experimental medicine (33) 33
sodium glucose co-transporter 2 inhibitor (33) 33
glycated hemoglobin a - analysis (32) 32
insulin resistance (32) 32
kidney - drug effects (32) 32
inhibitors (31) 31
kidneys (31) 31
mortality (31) 31
original (31) 31
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (506) 506
Spanish (5) 5
German (4) 4
French (3) 3
Chinese (1) 1
Danish (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Developing Treatments for Chronic Kidney Disease in the 21st Century
by Breyer, Matthew D., MD and Susztak, Katalin, MD, PhD
Seminars in nephrology, ISSN 0270-9295, 2016, Volume 36, Issue 6, pp. 436 - 447
Nephrology | Diabetic nephropathy | renal outcomes | SGTL2 | inflammation | Angiotensin | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Hypoglycemic Agents - therapeutic use | Oxidative Stress | Glycosaminoglycans - therapeutic use | Humans | Oleanolic Acid - analogs & derivatives | Diabetic Nephropathies - drug therapy | Sodium-Glucose Transporter 2 Inhibitors | Pyridoxamine - analogs & derivatives | Atrasentan | Drug Discovery | Mineralocorticoid Receptor Antagonists - therapeutic use | Pyrrolidines - therapeutic use | Renal Insufficiency, Chronic - drug therapy | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Canagliflozin - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Glucosides - therapeutic use | Oleanolic Acid - therapeutic use | Endothelin Receptor Antagonists - therapeutic use | Angiotensin Receptor Antagonists - therapeutic use | Benzhydryl Compounds - therapeutic use | Pyridoxamine - therapeutic use | Index Medicus | Please provide
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial
by Schernthaner, Guntram and Gross, Jorge L and Rosenstock, Julio and Guarisco, Michael and Fu, Min and Yee, Jacqueline and Kawaguchi, Masato and Canovatchel, William and Meininger, Gary
Diabetes care, ISSN 0149-5992, 09/2013, Volume 36, Issue 9, pp. 2508 - 2515
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Public health. Hygiene-occupational medicine | Public health. Hygiene | Diabetes. Impaired glucose tolerance | Miscellaneous | Biological and medical sciences | Endocrinopathies | Etiopathogenesis. Screening. Investigations. Target tissue resistance | Metabolic diseases | Medical sciences | Endocrine pancreas. Apud cells (diseases) | Hypoglycemic Agents - therapeutic use | Thiophenes - therapeutic use | Metformin - therapeutic use | Double-Blind Method | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Sulfonylurea Compounds - therapeutic use | Male | Treatment Outcome | Pyrazines - therapeutic use | Blood Glucose - drug effects | Canagliflozin | Female | Glucosides - therapeutic use | Aged | Sitagliptin Phosphate | Diabetes Mellitus, Type 2 - drug therapy | Triazoles - therapeutic use | Type 2 diabetes | Glucose metabolism | Care and treatment | Blood cholesterol | Hypoglycemic agents | Glucose | Pharmaceutical industry | Comparative analysis | Dextrose | Diabetes therapy | Side effects | Clinical trials | Diabetes | Hypoglycemia | Drug therapy | Weight | Index Medicus | Original Research
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Sodium glucose cotransporter 2 and dipeptidyl peptidase-4 inhibition: Promise of a dynamic duo
by Lingvay, Ildiko
Endocrine practice, ISSN 1530-891X, 07/2017, Volume 23, Issue 7, pp. 831 - 840
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemic Agents - therapeutic use | Dipeptides - therapeutic use | Metformin - therapeutic use | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Uracil - therapeutic use | Treatment Outcome | Linagliptin - therapeutic use | Diabetes Mellitus, Type 2 - metabolism | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Canagliflozin - therapeutic use | Piperidines - therapeutic use | Adamantane - therapeutic use | Sitagliptin Phosphate - therapeutic use | Glucosides - therapeutic use | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Hypoglycemia - chemically induced | Benzhydryl Compounds - therapeutic use | Adamantane - analogs & derivatives | Uracil - analogs & derivatives
Journal Article
Details down arrow
4. Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes
by Scheen, André J
Clinical pharmacokinetics, ISSN 0312-5963, 07/2017, Volume 56, Issue 7, pp. 703 - 718
Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Canagliflozin - pharmacokinetics | Dipeptides - therapeutic use | Dipeptides - pharmacokinetics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Linagliptin - pharmacokinetics | Treatment Outcome | Glucosides - pharmacokinetics | Linagliptin - therapeutic use | Diabetes Mellitus, Type 2 - metabolism | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Dipeptidyl-Peptidase IV Inhibitors - pharmacokinetics | Canagliflozin - therapeutic use | Adamantane - therapeutic use | Sitagliptin Phosphate - therapeutic use | Glucosides - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Benzhydryl Compounds - therapeutic use | Adamantane - pharmacokinetics | Benzhydryl Compounds - pharmacokinetics | Sitagliptin Phosphate - pharmacokinetics | Adamantane - analogs & derivatives
Journal Article
Details down arrow
5. Full Text Lower risk of death with SGLT2 inhibitors in observational studies: Real or bias?
by Suissa, Samy
Diabetes care, ISSN 0149-5992, 01/2018, Volume 41, Issue 1, pp. 6 - 10
Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemic Agents - therapeutic use | Follow-Up Studies | Bias | Diabetes Mellitus, Type 2 - genetics | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Mortality | Risk Factors | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Diabetes Mellitus, Type 2 - epidemiology | Randomized Controlled Trials as Topic | Canagliflozin - therapeutic use | Cardiovascular Diseases - epidemiology | Observational Studies as Topic | Glucosides - therapeutic use | Benzhydryl Compounds - therapeutic use | Insulin - therapeutic use | Cohort Studies | Health care | Drugs | Uncertainty | Peptidase | Diabetes mellitus | Health risks | Clinical trials | Risk | Glucose | Insulin | Patients | Prescription drugs | Inhibitors | Sodium | Death | Diabetes | Cardiovascular diseases | Diabetes mellitus (non-insulin dependent) | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text The Mechanisms and Therapeutic Potential of SGLT2 Inhibitors in Diabetes Mellitus
by Vallon, Volker
Annual review of medicine, ISSN 0066-4219, 1/2015, Volume 66, Issue 1, pp. 255 - 270
body weight | sodium-glucose cotransporter | glucose reabsorption | glomerular hyperfiltration | hypertension | gluconeogenesis | diabetic nephropathy | Hypoglycemic Agents - therapeutic use | Thiophenes - therapeutic use | Sodium-Glucose Transporter 2 - metabolism | Humans | Diabetes Mellitus, Type 1 - metabolism | Diabetes Mellitus, Type 2 - metabolism | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Diabetes Mellitus, Type 1 - drug therapy | Kidney - metabolism | Canagliflozin | Glucosides - therapeutic use | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Glucose metabolism | Health aspects | Methods | Diabetes therapy | Hyperglycemia | Blood pressure | Inhibitor drugs | Diabetes | Glucose | Hypoglycemia | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text SGLT2 inhibitors and incretin agents: Associations with alanine aminotransferase activity in type 2 diabetes
by Bajaj, H.S and Brown, R.E and Bhullar, L and Sohi, N and Kalra, S and Aronson, R
Diabetes & metabolism, ISSN 1262-3636, 12/2018, Volume 44, Issue 6, pp. 493 - 499
Type 2 diabetes | Alanine aminotransferase | Antihyperglycaemic agents | Non-alcoholic fatty liver disease | SGLT2 inhibitors | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Hypoglycemic Agents - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Humans | Middle Aged | Male | Treatment Outcome | Alanine Transaminase - blood | Canada | Diabetes Mellitus, Type 2 - blood | Canagliflozin - therapeutic use | Liraglutide - therapeutic use | Aged, 80 and over | Sitagliptin Phosphate - therapeutic use | Female | Glucosides - therapeutic use | Registries | Aged | Retrospective Studies | Incretins - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis
by Shyangdan, Deepson S and Uthman, Olalekan A and Waugh, Norman
BMJ open, ISSN 2044-6055, 02/2016, Volume 6, Issue 2, pp. e009417 - e009417
Hypoglycemic Agents - therapeutic use | Metformin - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Sodium-Glucose Transporter 2 Inhibitors | Weight Loss - drug effects | Diabetes Mellitus, Type 2 - blood | Sorbitol - analogs & derivatives | Canagliflozin - therapeutic use | Bayes Theorem | Glucosides - therapeutic use | Blood Pressure - drug effects | Diabetes Mellitus, Type 2 - drug therapy | Drug Therapy, Combination | Benzhydryl Compounds - therapeutic use | Sorbitol - therapeutic use | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus
by Scheen, André J
Drugs (New York, N.Y.), ISSN 0012-6667, 01/2015, Volume 75, Issue 1, pp. 33 - 59
Pharmacology & Pharmacy | Toxicology | Life Sciences & Biomedicine | Science & Technology | Hypoglycemic Agents - therapeutic use | Thiophenes - therapeutic use | Glucosides - pharmacology | Thiophenes - adverse effects | Humans | Thiophenes - pharmacology | Sodium-Glucose Transporter 2 - antagonists & inhibitors | Hypoglycemic Agents - pharmacology | Benzhydryl Compounds - adverse effects | Canagliflozin | Glucosides - therapeutic use | Benzhydryl Compounds - pharmacology | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Hypoglycemic Agents - adverse effects | Glucosides - adverse effects
Journal Article
Details down arrow